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ABSTRACT
Objective: The current study involves the fabrication of oral bilayer matrix designs of a combination of two drugs, metoprolol succinate and 
atorvastatin calcium, the optimization of their in vitro release and characterization using the design expert software. Metoprolol succinate, a β1-
selective adrenergic receptor blocking agent, is used in the management of hypertension has a half-life of approximately 4–5 h; thus, there is the need 
to use extended-release formulation for prolonged action. Atorvastatin is a hydroxymethylglutaryl-coenzyme A reductase inhibitor, an antilipidemic, 
used to lower blood cholesterol. The rationale for this fixed-dose combination is to coadminister two drugs acting by different mechanisms of action 
together, reduce dosing frequency, and increase patient compliance.
Methods: A 32 factorial design was selected to analyze the effect of critical factors, polymer concentration of Kollidon sustained release (SR), and Eudragit 
RS and their interaction on the in vitro release of the SR part containing metoprolol succinate. The drug release at 2 h (Q2), 8 h (Q8), and 20 h (Q20) was 
taken as responses. The blends of both layers were prepared, evaluated for precompression characteristics, and compressed by direct compression. The 
compressed bilayer tablets were evaluated for their hardness, weight variation, friability, content uniformity, diameter, and in vitro release.
Result and Conclusion: The release profile indicates Higuchi’s kinetics. Contour and surface response plots show significant interaction among 
the formulation variables. Formulation MS06 containing 70 mg Kollidon SR and 10 mg Eurdragit RS was found to be the optimized formulation, 
controlling the drug release for a 24 h period.
Keywords: Bilayer tablet, Metoprolol succinate, Atorvastatin calcium, Kollidon sustained release, Eudragit RS, Design expert.
INTRODUCTION
The multilayered tablet concept has been utilized to develop sustained 
release (SR) formulations and coadministers two drugs as a fixed-dose 
combination [1].
Hypertension is the most common cardiovascular disease. The 
prevalence of hypertension increases with advancing age. Metoprolol 
succinate is a β1-selective adrenergic receptor blocking agent used 
in the management of hypertension. The half-life of drug is relatively 
short, approximately 4–6 h, and in normal course of therapy, drug 
administration is required every 4–6 h, thus there is the need for the 
use of extended-release formulation for prolong action and to improve 
patient compliance [2,3].
Antilipidemic agents are an important group of drugs for the treatment 
of ischemia and hypertension. Atorvastatin is a hydroxymethylglutaryl-
coenzyme A reductase inhibitor and has a longer duration of action, 
and the initial effects are cumulative over many days and moreover for 
patient compliance in case of angina patients; a rapid onset of action is 
necessary for immediate pain relief [4,5].
The present study encompasses a combination drug therapy, 
recommended for treatment of hypertension to allow medications of 
different mechanisms of action to complement each other and together 
effectively lower blood pressure at lower than maximum doses of each.
The rationale for this fixed-dose combination is to coadminister two 
drugs acting by different mechanisms of action together reduce dosing 
frequency and increase patient compliance.
Kollidon SR is a relatively new extended-release matrix excipient. It 
consists of 80% polyvinyl acetate (PVA) and 20% povidone (PVP) in 
a physical mixture, stabilized with 0.8% sodium lauryl sulfate (SLS), 
and 0.2% colloidal silica. It shows excellent flowability and can be 
used as an excipient for direct compression. The amorphous nature of 
PVA along with its unusually low glass transition temperature imparts 
unique characteristics to a matrix formulation. The SR properties are 
unaffected by ions or salts [6]. The current work aims at design and 
statistical optimization using 32 factorial approach (using Stat Ease Inc., 
Minneapolis, MN, USA, Design Expert® 10 software) of a bilayer tablets 
of atorvastatin calcium as immediate release (IR) and metoprolol 
succinate as SR using Kollidon SR as a novel directly compressible SR 
polymer.
MATERIALS AND METHODS
Atorvastatin calcium was gifted by Wanbury Ltd., Mumbai, metoprolol 
succinate was gifted by Dr. Reddy’s Ltd., Hyderabad, Kollidon SR was 
gifted by VerGo Pharma, Goa, Eudragit RS by Evonik India, Mumbai, and 
MCC pH 102 and other excipients from Arihant Chemicals, Mumbai.
Methodology
Formulation of atorvastatin calcium IR component
The dose of the drug in the IR layer is 10 mg. The blend for IR layer 
was prepared by mixing drug with super disintegrant crospovidone and 
surfactant SLS geometrically and subsequently adding other ingredients 
as per Table 1. The ingredients were mixed in mortar and pestle for 
15 min, mixture passed through sieve# 80, and finally, magnesium 
stearate and aerosil were blended into and mixed thoroughly. The 
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blends were evaluated for precompression parameters such as bulk 
density, tapped density, angle of repose, and Carr’s compressibility 
index. The final weight of the tablet was 110 mg, compressed using 
Rimek Mini Press II MT (Karnavati Engineering Private Ltd.) [7].
Formulation of metoprolol succinate SR component using 32 
factorial design
To design the SR layer for the bilayer tablet, a 32 full factorial design 
containing two factors at three levels was applied. Different preliminary 
trial batches were taken to ascertain concentrations of independent 
variables to be used in 32 factorial design. The independent variables used 
were a concentration of Kollidon SR and concentration of Eudragit RS. 
Table 2 summarizes the level of variables according to the experimental 
design. The amount of Kollidon SR per tablet is chosen at three levels from 
30 mg to 50 mg to 70 mg per tablet. The effect of Eudragit RS was studied 
at three levels (0, 10, and 20 mg) to check its effect on drug release.
The polynomial equation generated by the design software Design 
Expert 10, State Ease Inc., is as follows:
Y=b0+b1X1+b2X2+b12X1X2+b11X12+b22X22 (1)
Where, Y is a response (dependent variable), b0 is an intercept, b1 to b22 
are regression coefficients, and X1 and X2 are independent formulation 
variables
Nine batches were prepared as per Table 3, wherein the amount 
of polymers Kollidon SR (X1) and Eudragit RS (X2) were varied to 
compare the rate of drug release. The blend was prepared by mixing 
drug and excipients in a laboratory cube blender for 15 min and finally 
magnesium stearate and aerosil were blended into. The blends were 
evaluated for precompression parameters such as bulk density, tapped 
density, angle of repose, and Carr’s compressibility index. The final 
weight of the tablet was 170 mg, compressed using Rimek Mini Press II 
MT (Karnavati Engineering Private Ltd.) [8,9].
Formulation of bilayered tablet of atorvastatin calcium and 
metoprolol succinate
To prepare the bilayered tablet, first the SR blend of metoprolol 
succinate was added manually into the die cavity of the tablet 
compression machine (Rimek Mini Press II MT (Karnavati Engineering 
Private Ltd.) and compressed lightly. Followed by which the IR blend of 
atorvastatin calcium was added and compressed to obtain the bilayered 
tablet. All the nine batches of SR metoprolol succinate SR layer were 
compressed with the optimized batch AT01 of IR and were further 
evaluated for post-compression characteristics [9].
Evaluation of post-compression parameters of bilayered tablet
Physical tests such as hardness, thickness, friability, and uniformity of 
weight were performed as per USP using Monsanto hardness tester 
(Pathak Electrical Works), Vernier caliper (Bliss Classic), and Roche 
Friabilator (Pathak Electricals), respectively [8-10].
Drug excipient compatibility
Drug-excipient compatibility was determined using Fourier transform 
infrared and differential scanning calorimetry (DSC) studies.
Drug content
UV spectrophotometric method for simultaneous estimation of 
atorvastatin calcium and metoprolol succinate was developed on the 
guidelines of the method as per Wankhede et al. The tablet was crushed, 
contents extracted with methanol, and further diluted with phosphate 
buffer pH 6.8 and drug content analyzed [11].
In vitro disintegration time
Disintegration time for IR layer of atorvastatin calcium was determined 
using USP tablet disintegration apparatus with phosphate buffer 
of pH 6.8 as medium. The volume of medium used was 900 mL and 
temperature was 37±0.5°C. The time taken for complete disintegration 
of the IR layer was measured [10].
In vitro drug release
The in vitro drug release of bilayered tablet was studied using USP type II 
paddle apparatus using 900 ml phosphate buffer pH 6.8 at 50 rpm at 
37±0.5°C (OGD dissolution method). The samples were withdrawn at 
predetermined time intervals for a period of 24 h and replaced with 
the fresh buffer. The samples were filtered through 0.45 µm membrane 
filter, suitably diluted, and analyzed using double beam UV-visible 
spectrophotometer. The content of drug was calculated using the 
simultaneous equation method developed and validated for the drug 
combination. The test was performed in triplicate. Since reproducible 
Table 1: Formulation of atorvastatin calcium blends
Ingredients (mg/tab) Formulations
AT01 AT02 AT03 AT04
Atorvastatin calcium 10 10 10 10
Crospovidone 10 10 5 5
SLS 1 0.5 1 0.5
MCC pH 102 30 30 30 30
Lactose 50 50.5 55 55.5
Calcium carbonate 8 8 8 8
Magnesium stearate 0.5 0.5 0.5 0.5
Aerosil 0.5 0.5 0.5 0.5
Total tablet weight (mg) 110 110 110 110
SLS: Sodium lauryl sulfate, MCC: Microcrystalline cellulose
Table 2: Experimental design for Metoprolol succinate 





Concentration of Kollidon 
SR per tablet (mg)
Concentration of Eudragit 





Table 3: Formulation blends of metoprolol succinate layer
Ingredients MS01 MS02 MS03 MS04 MS05 MS06 MS07 MS08 MS09
Metoprolol succinate 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5 47.5
Kollidon SR 30 50 70 30 50 70 30 50 70
Eudragit RS 100 0 0 0 10 10 10 20 20 20
MCC pH 102 89 69 49 79 59 39 69 49 29
Magnesium stearate 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5
Aerosil 1 1 1 1 1 1 1 1 1
Sunset yellow FCF 1 1 1 1 1 1 1 1 1
Total tablet weight (mg) 170 170 170 170 170 170 170 170 170
SR: Sustained release
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data were obtained (standard deviation±4%), hence average values 
were considered.
Statistical analysis
The statistical analysis was done using Design Expert® 10 software. The 
responses analyzed were the drug release Q2 (at 2 h), Q8 (at 8 h), and 
Q20 (20 h). Contribution of each factor was evaluated as responses, 
and graphical representation was seen through the contour plots and 
3D surface plots. Contribution of each factor on the responses was 
evaluated by two-way analysis of variance (ANOVA). The significance 
level was considered as p<0.05 [10].
Kinetic modeling for drug release
Mechanism of drug release was studied by analyzing the dissolution 
data through zero order, first order, and Higuchi’s and Korsmeyer-
Peppas equations [12].
Accelerated stability study
The optimized batch of bilayered tablet was subjected to stability study 
in accordance with ICH guidelines. The bilayered tablets wrapped in 
aluminum foil were kept at 40°C, 75% RH in a stability chamber (Patel 
Scientific Instruments) for 3 months. Subsequently, the tablets were 
analyzed for drug content, in vitro release, and other physicochemical 
characteristics.
RESULTS AND DISCUSSION
Pre-compression characteristics such as bulk density, tapped density, 
angle of repose, and Carr’s compressibility index were evaluated for 
both the blends and are tabulated in Tables 4 and 5. The angle of repose 
and Carr’s compressibility values indicated good flow properties and 
compressibility of both the blends. The angle of repose ranges from 
22.04±0.55 to 23.67±0.98 and 12.64±0.55 to 21.57±0.62 for IR and SR 
blends, respectively. The SR blends exhibit better flow properties as the 
amount of Kollidon SR polymer increases from 30 to 70 mg per tablet 
which makes Kollidon SR a good directly compressible excipient.
Post-compression characteristics of bilayered tablet
The results of post-compression characteristics – hardness, thickness, 
weight variation, friability, disintegration time (for IR layer), and drug 
content are as tabulated in Table 6. A linear relationship was observed 
between the concentration of Kollidon SR and the hardness of the tablet. 
The IR component of the bilayer tablet disintegrates within 90–110 s as 
required for the formulation.
Drug excipient compatibility
DSC studies
From the DSC study, the thermograph shows the melting point of pure 
drug metoprolol succinate was found at 138°C; atorvastatin calcium 
was at 159.95°C which is similar as reported in the literature. The 
results of DSC study are as depicted in Fig. 1. The thermograph of pure 
drugs and mixture of drugs does not show a significant change in their 
respective melting points. The DSC study of formulation mixtures also 
shows no significant change to that of the melting point of pure drug, 
which rules out drug excipient incompatibilities.
In vitro drug release
The cumulative percent drug released for AT01, AT02, AT03, and AT04 
formulations was found to be 100.87%, 71.11%, 85.97%, and 46.42%, 
respectively, at 45 min. The results as depicted in Fig. 2 show that the 
maximum amount of drug was released from the formulation AT01 
Table 4: Pre-compression characteristics of atorvastatin calcium blends
Formulation code Angle of reposea Bulk density (g/ml)a Tapped densitya (g/ml) Carr’s indexa (%)
AT01 22.04±0.55 0.43±0.05 0.54±0.02 17.30
AT02 21.54±0.41 0.47±0.04 0.55±0.08 14.54
AT03 23.67±0.98 0.42±0.08 0.54±0.06 20.75
AT04 22.87±0.71 0.41±0.04 0.52±0.04 19.60
aMean±SD, n=3. SD: Standard deviation
Table 5: Pre-compression characteristics of metoprolol succinate blends
Formulation code Angle of reposea Bulk densitya (g/ml) Tapped densitya (g/ml) Carrs index (%)
MS01 21.57±0.62 0.41±0.08 0.46±0.04 11.76
MS02 20.14±0.22 0.42±0.05 0.48±0.11 12.8
MS03 18.54±0.87 0.43±0.07 0.49±0.09 13.33
MS04 19.31±1.0 0.38±0.1 0.42±0.08 10.52
MS05 18.54±0.32 0.36±0.08 0.41±0.06 12.28
MS06 16.66±0.54 0.35±0.04 0.42±0.05 15.78
MS07 15.41±0.87 0.36±0.09 0.40±0.08 10.0
MS08 12.64±0.55 0.34±0.08 0.39±0.09 12.8
MS09 14.65±0.21 0.33±0.04 0.38±0.24 13.15
aMean±SD, n=3. SD: Standard deviation









Friabilitya (%) DT for IR 
layer (s)
Drug contenta 
 (SR layer) (%)
Drug contenta  
(IR layer) (%)
MS01 8.5±0.23 4 280±0.52 0.29±0.0021 90 98.12±0.87 99.21±0.57
MS02 10.3±0.35 4 280±0.37 0.41±0.0074 98 99.87±1.21 99.57±0.64
MS03 11.2±0.87 4 280±0.97 0.51±0.0041 95 99.35±0.54 98.64±1.28
MS04 10.5±0.47 4 280±0.65 0.38±0.005 97 99.84±0.98 99.24±0.55
MS05 11.0±0.17 4 280±0.86 0.63±0.0087 100 98.67±1.32 98.54±0.97
MS06 10.1±0.61 4 280±0.46 0.49±0.0097 93 98.12±1.5 99.69±1.64
MS07 10.5±0.31 4 280±0.48 0.55±0.0035 99 98.79±0.77 98.82±1.47
MS08 11.0±0.45 4 280±0.87 0.17±0.0047 110 99.54±0.68 99.16±0.57
MS09 11.4±0.36 4 280±0.14 0.26±0.0046 98 99.34±0.41 98.54±1.22
aMean±SD, n=3. SD: Standard deviation
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when compared to other formulations. This is due to the optimum 
concentration level of superdisintegrant crospovidone and surfactant 
sodium lauryl sulfate in the formulation. Hence, formulation AT01 was 
confirmed as an optimized IR layer, which was further selected to be 
compressed against the nine batches of SR layer of metoprolol succinate 
as designed using Design Expert Software.
The release profile of the SR metoprolol succinate component from the 
nine batches of bilayer tablets is as given in Fig. 3. All the factorial batches 
showed drug release up to 12–24 h depending on the concentration 
of Kollidon SR polymer. Formulation MS01, MS04, and MS07 showed 
a rapid dissolution profile from 12 to 18 h which was faster than the 
required release for a once a day formulation. These three batches 
contain 18% of Kollidon SR which is insufficient to control the release 
up to 24 h. The rest of the batches controlled the drug release up to 
24 h, with Kollidon SR concentration varying between 30% and 40% 
(50–70 mg per tablet). Kollidon SR showed excellent controlled drug 
release in this range. Formulation MS06 showed optimum drug release 
of 94.31% at 24 h with f2 value of 74 when compared to marketed 
formulation (Metpure XL) and complying with USP requirements for 
release as given in Table 7. Eudragit RS plays a significant role as to 
control the burst release that occurs in the initial hour. It was observed 
that formulations MS01, MS02, and MS03 with Kollidon SR polymer and 
devoid of Eudragit RS, showed a significant burst release effect in the 
initial 1–2 h of release as compared to the rest of the formulations. The 
release for formulations MS01, MS02 and MS03 at end of 1 hour was 
31.23%, 25.22% and 22.02% respectively which is not in the desired 
limit of not more than 25% as per USP requirements (Table 7). Kollidon 
SR, is a polymer containing 80% insoluble PVA and 20% soluble 
PVP. When in contact of the dissolution media the water soluble PVP 
dissolves forming pores for release of the dug. The sudden burst effect 
has been attributed due to this phenomenon. Inclusion of Eudragit RS 
into the formulation controls the burst release and aids kollidon SR in 
controlling the drug release over a 24 hour period. For formulations 
MS05, MS06, MS08 and MS09 containing 10-20mg of Eudragit RS per 
tablet the release at the end of 1 hour was 22.44%, 16.82%, 21.45% 
and 10.55% respectively. This clearly envisages the role of Eudragit RS 
in controlling the burst release which was observed with Kollidon SR 
alone. The release profile of the optimum batch MS06 of bilayer tablet 
is depicted in Fig. 4. The Immediate release atorvastatin component 
releases 100.87% the drug in 45 min whereas the release of metoprolol 
succinate component is sustained upto 24 h0urr.
The in vitro release data were fitted into various kinetic equations. The 
correlation coefficients are indicated in Table 8. It can be postulated 
that in vitro release profile of all the metoprolol succinate matrix 
formulations could be best expressed by the Higuchi model. The plot 
showed high linearity in comparison to other release kinetic equations. 
Fig. 1: Compatibility studies of drugs and excipients using differential scanning calorimetry
Fig. 2: Cumulative drug release profiles of atorvastatin calcium 
immediate release component
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Release of drug from the matrix tablet generally follows diffusion for 
water soluble drug. To confirm diffusion mechanism, the data were 
fitted into Korsmeyer et al.’s equation. For matrix tablet, n value 0.5 
indicates diffusion controlled value to near 1.00 indicates erosion. 
Intermediate value suggests simultaneous diffusion and erosion 
contributed to overall release mechanism.
Statistical optimization of the bilayer tablet
To describe the entire dissolution profile, three time points were 
considered in the design expert software. Percentages of drug release 
at 2, 8, and 20 h (Q2, Q8, and Q20) were considered as responses as 
tabulated in Table 9. As observed formulations MS02, MS03, MS05, 
MS06, and MS08 control the drug release up to a 24 h period. This is 
mainly attributed the excellent control release property of Kollidon 
SR polymer. Further, Eudragit RS helps control the burst release 
significantly as observed in formulation MS06.
ANOVA
ANOVA of the responses indicated that response surface models 
developed for Q2, Q8, and Q20 was significant and adequate. Influence 
of variables on the responses is indicated in Table 10. From the ANOVA 
analysis, it can be observed that Kollidon SR polymer has effect on all 
responses Q2, Q8, and Q20 (since p<0.5). This enforces the fact that it 
is the main release-retarding polymer that controls the drug release 
up to 24 h. It is also observed from the ANOVA result that Eudragit 
RS has a significant effect at Q2. This reinforces the significant role of 
the polymer to control the burst release of the drug in the initial 2 h. 
Eudragit RS has a less significant effect on drug release at response Q8 
and Q20.
Model summary statistics
Model summary statistics for the selected significant models are shown 
in Table 11. R2 values indicate a high level of correlation between 
experimental and predicted responses. The closeness of the adjusted 
and predicted R2 values explains the reliability of the model.
Mathematical equations
Mathematical relationships generated from design expert for the 
studied response variables are expressed as equations I, II, and III. The 
equation in terms of actual factors can be used to make predictions 





Figs. 6-11 represent the contour plot and three dimensional analysis 
for the studied response properties of release at 2 h, 8 h and 20 h. From 
the contour plot it can be concluded that the release in 2 h decreases 
with augmentation of both the variables, concentration of Kollidon SR 
and Concentration of Eudragit RS. Eudragit RS is observed to control 
the burst release in the initial 1–2 h. This effect is significantly observed 
in the Q2 response after which it can be observed that Kollidon SR is 
primarily involved in controlling the release. From the contour plot 
it was evident that the declining trend was obtained with ascending 
Fig 3: Cumulative drug release profiles of metoprolol succinate sustained release component
Fig. 4. Dissolution profile of optimized batch of bilayer tablet
Table 7: USP requirements for release of metoprolol succinate 
extended release
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Fig. 5: Release kinetics of optimized batch MS06
Fig. 6: Contour plot for response Q2
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order of Kollidon SR. The plots for Q8 and Q20 demonstrate that the 
concentration of kollidon SR significantly controls the release of 
metoprolol succinate from the matrix formulation after 2 hours. As 
observed from the surface response plots, as the concentration of 
Kollidon SR increases from 30 mg/tablet to 70 mg/tablet, the release at 
the response points is retarded. The contour plot of Q8 and Q20 as well 
as the surface response plot shows major role of Kollidon SR controlling 
the drug release. This is mainly attributed to the plastic behaviour of 
the hydrophobic polymer PVA in Kollidon SR which shows effect is 
controlling drug release of a water soluble drug metoprolol succinate 
from the matrix formulation.
Table 8: Correlation coefficients of different pharmacokinetic models for release
Formulation Zero order (r2) First order (r2) Higuchi (r2) Peppas (n) Hixon Crowel (r2)
MS01 0.6401 0.786 0.8594 0.7569 0.8973
MS02 0.8975 0.8524 0.9942 0.7436 0.8891
MS03 0.9439 0.8947 0.9908 0.7546 0.9621
MS04 0.5828 0.6618 0.8228 0.7331 0.7757
MS05 0.9365 0.8639 0.9943 0.7656 0.8113
MS06 0.9595 0.9248 0.9906 0.7546 0.9621
MS07 0.8421 0.9051 0.9625 0.766 0.9379
MS08 0.9483 0.8371 0.9906 0.7848 0.8128
MS09 0.9814 0.9177 0.9559 0.8069 0.9617
Table 9: Percentage drug responses at 2 h, 8 h, and 20 h
Formulation code Q2 (%) Q8 (%) Q20 (%)
MS01 37.46 94.12 100
MS02 29.87 60.47 92.17
MS03 24.5 48.8 84.38
MS04 42.2 90.05 100
MS05 27.21 59.47 96.74
MS06 20.54 48.97 82.34
MS07 31.56 65.49 100
MS08 23.65 56.21 92.64
MS09 15.87 41.54 76.54
Table 10: ANOVA influence of formulation variables on response 
factors
Response factor F value P>F
Q2 30.73 0.0007
X1 (Kollidon SR concentration) 52.52 0.0004
X2 (Eudragit RS concentration) 8.93 0.0244
Q8 20.78 0.0020
X1 (Kollidon SR concentration) 36.71 0.0009
X2 (Eudragit RS concentration) 4.86 0.0697
Q20 27.96 0.0009
X1 (Kollidon SR concentration) 54.99 0.0003
X2 (Eudragit RS concentration) 0.93 0.3726
SR: Sustained release, ANOVA: Analysis of variance
Fig. 7: Contour plot for response Q8
Table 11: Model summary - influence of formulation variables 
on response factors
Response SD Adjusted R2 Predicted R2
Q2 8.229 0.8814 0.8055
Q8 18.131 0.8318 0.6905
Q20 8.690 0.8708 0.7855
SD: Standard deviation
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CONCLUSION
The contour plots and response surface methodology using 
Design-Expert Software were used to optimize the bilayer tablet of 
metoprolol succinate SR and atorvastatin calcium IR wherein the 
work envisages the use of the Kollidon SR polymer as a significant 
polymer for direct compression of the bilayer tablet. It controls 
the release of water-soluble metoprolol succinate drug for the 
desired period of time. With the advantage of pH-independent 
release, it can control the drug release up to 24 h. Further, Eudragit 
RS reinforces the effect in addition to controlling the burst effect 
in the formulations with Kollidon alone. Formulation MS06 with 
70 mg Kollidon SR and 10 mg Eudragit RS is the best optimized 
formulation. The influence of the factors can be closely studied on 
the responses, i.e., drug release at various time points. The direct 
compression technique for manufacture of this bilayer tablet is a 
safe and effective tool for patients taking the drugs as monotherapy 
as well as for drugs which can be given as fixed-dose combinations 
for lifestyle diseases.
Fig. 8: Contour plot for response Q20
Fig. 9: Surface response plot for response Q2
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